GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (OTCPK:MLLCF) » Definitions » Price-to-Owner-Earnings

MLLCF (Molecular Partners AG) Price-to-Owner-Earnings : (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Molecular Partners AG Price-to-Owner-Earnings?

As of today (2024-12-14), Molecular Partners AG's share price is $4.55. Molecular Partners AG does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Molecular Partners AG's Price-to-Owner-Earnings or its related term are showing as below:

During the past 11 years, the highest Price-to-Owner-Earnings of Molecular Partners AG was 6.84. The lowest was 1.62. And the median was 1.90.


MLLCF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.405
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-12-14), Molecular Partners AG's share price is $4.55. Molecular Partners AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.17. Therefore, Molecular Partners AG's PE Ratio (TTM) for today is At Loss.

As of today (2024-12-14), Molecular Partners AG's share price is $4.55. Molecular Partners AG's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.05. Therefore, Molecular Partners AG's PE Ratio without NRI for today is At Loss.

During the past 11 years, Molecular Partners AG's highest PE Ratio without NRI was 6.18. The lowest was 0.00. And the median was 1.84.


Molecular Partners AG Price-to-Owner-Earnings Historical Data

The historical data trend for Molecular Partners AG's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Price-to-Owner-Earnings Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.83 -

Molecular Partners AG Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Molecular Partners AG's Price-to-Owner-Earnings

For the Biotechnology subindustry, Molecular Partners AG's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Price-to-Owner-Earnings falls into.



Molecular Partners AG Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Molecular Partners AG's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.55/-1.86
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Partners AG  (OTCPK:MLLCF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Molecular Partners AG Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG Headlines